Sunitinib

Title	Average Rating
Tumoral angiogenesis: review of the literature.	50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.	50.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors.	70.00%
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.	70.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.	90.00%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).	70.00%
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603.	80.00%
42 year old man. Kidney cancer	90.00%
Clinical management of adrenocortical carcinoma	60.00%

Languages